Rhabdomyolysis and Acute Renal Failure Induced by Combination Lovastatin and Gemfibrozil Therapy
Authors: Gary E. Marais
Journal: Annals of Internal Medicine (1990)

Brief Reports1 February 1990Rhabdomyolysis and Acute Renal Failure Induced by Combination Lovastatin and Gemfibrozil TherapyGary E. Marais, MB, ChB, Kerry K. Larson, MDGary E. Marais, MB, ChB, Kerry K. Larson, MDAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-112-3-228 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptLovastatin is a new lipid-lowering drug that has shown great promise in the treatment of patients with hypercholesterolemia (1, 2). It is the first available agent in a new class of drugs that inhibit the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase, which catalyzes the rate-limiting step in cholesterol synthesis (3). Lovastatin is well tolerated and few severe adverse effects have been reported (4). Myopathy, defined as muscle pain or weakness associated with markedly elevated creatine kinase levels, has a reported incidence of 0.5% (4). Rhabdomyolysis has been reported in 30% of patients when the drug is used concomitantly with immunosuppressive drugs...References1. HavelHunninghakeIllingworth RDD. Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study. Ann Intern Med. 1987;107:609-15. LinkGoogle Scholar2. . Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study. JAMA. 1986;256:2829-34. CrossrefMedlineGoogle Scholar3. Grundy S. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med. 1988;319:24-33. CrossrefMedlineGoogle Scholar4. Tobert J. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol. 1988;62:28J-34J. CrossrefMedlineGoogle Scholar5. NormanIllingworthMunsonHosenpud DDJJ. Myolysis and acute renal failure in a heart-transplant patient receiving lovastatin [Letter]. N Engl J Med. 1988;318:46-7. CrossrefMedlineGoogle Scholar6. EastAlivizatosGrundyJonesFarmer CPSPJ. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation [Letter]. N Engl J Med. 1988;318:47-8. CrossrefMedlineGoogle Scholar7. Tobert J. Reply. N Engl J Med. 1988;318:48. MedlineGoogle Scholar8. ReavenWitztum PJ. Lovastatin, nicotinic acid, and rhabdomyolysis. Ann Intern Med. 1988;109:597-8. LinkGoogle Scholar9. AyanianFuchsStone JCR. Lovastatin and rhabdomyolysis [Letter]. Ann Intern Med. 1988;109:682-3. LinkGoogle Scholar10. CorpierJonesSuki CPW. Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients. JAMA. 1988;260:239-41. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: From Jerry L. Pettis Memorial Veterans Hospital, Loma Linda, California. For current author addresses, see end of text. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByNutritional and nonnutritional management of the nephrotic syndromeThe Glitazars Paradox: Cardiotoxicity of the Metabolically Beneficial Dual PPARα and PPARγ ActivationDrug-Drug Interactions in Acute Coronary Syndrome Patients: Systematic ReviewDrug Class Combination–Associated Acute Kidney InjurySafety and efficacy of fibrate–statin combination therapy compared to fibrate monotherapy in patients with dyslipidemia: A meta-analysisSafety and efficacy of statin treatment alone and in combination with fibrates in patients with dyslipidemia: a meta-analysisNutritional and Non-nutritional Management of the Nephrotic SyndromePersistent Use of Against-Label Statin-Fibrate Combinations from 2003-2009 Despite United States Food and Drug Administration Dose RestrictionsEvaluation of the synergistic adverse effects of concomitant therapy with statins and fibrates on rhabdomyolysisRecovery Time in a Case of Gemfibrozil and Simvastatin-Associated RhabdomyolysisToxic MyopathiesEffectiveness of Statin-Gemfibrozil Combination Therapy in Patients With Mixed Hyperlipidemia: Experience of a Community Lipid Clinic and Safety Review From the LiteratureChapter 32 Toxic myopathiesCombination Therapy with an HMG-CoA Reductase Inhibitor and a Fibric Acid DerivativeA safety look at currently available statinsCerivastatin-Induced Rhabdomyolysis: 11 Case ReportsMyopathy and rhabdomyolysis with lipid-lowering drugsAcquired MyopathiesEl tratamiento farmacológico hipolipemiante con estatinas debería ser el más indicado en los individuos con hipercolesterolemia e hipertrigliceridemiaConséquences inattendues dˈun effet indésirable attendu de la cérivastatineRhabdomyolysis and HMG-CoA Reductase InhibitorsStatin—Fibrate Combination TherapyRhabdomyolysis due to combination therapy with cerivastatin and gemfibrozilRhabdomyolysisEffects of bezafibrate plus policosanol or placebo in patients with combined dyslipidemia: A pilot studyInfluenza vaccine—a possible trigger of rhabdomyolysis induced acute renal failure due to the combined use of cerivastatin and bezafibratePharmacotherapy of hypercholesterolaemia: statins in clinical practiceLovastatin Therapy for X-Linked Adrenoleukodystrophy: Clinical and Biochemical Observations on 12 PatientsUse of Statins and Fibrates in Hyperlipidemic Patients with Neuromuscular DisordersNathalie M. Leung, MD, Teik Chye Ooi, MBBS, FRCPC, FRACP, and Matthew J. McQueen, MBChB, FRCPC, PhDEffect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemiaA double-blind placebo controlled trial of simvastatin for the treatment of dyslipidaemia in renal allograft recipientsClinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitorsLong-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disordersRhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapyMetabolism and Drug Interactions of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in Transplant PatientsLong-Term Efficacy and Safety of Fenofibrate and a Statin in the Treatment of Combined HyperlipidemiaTreatment of Hyperlipidemia in the Nephrotic SyndromeTubular and Metabolic Dysfunction Following TransplantationInhibition of cholesterol biosynthesis by squalene epoxidase inhibitor avoids apoptotic cell death in L6 myoblastsLong-term Treatment With Pravastatin Alone and in Combination With Gemfibrozil in Familial Type IIB Hyperlipoproteinemia or Combined HyperlipidemiaDrug Interactions with Agents Used in the Treatment of Cardiovascular DiseaseIntraoperative Rhabdomyolysis in a Patient Receiving Pravastatin, a 3-Hydroxy-3-methylglutaryl Coenzyme A (HMG CoA) Reductase InhibitorApproaches to The Treatment of Hyperlipidemia in the Solid Organ Transplant RecipientLong-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease.Comparative Evaluation of the Safety and Efficacy of HMG-CoA Reductase Inhibitor Monotherapy in the Treatment of Primary HypercholesterolemiaDual bezafibrate-simvastatin therapy for combined hyperlipidaemiaCombined Treatment with Pravastatin and Gemfibrozil in Patients with Refractory Familial Combined Hyperlipidaemia3-Hydroxy-3-methylglutaryl Coenzyme A Reductase InhibitorsPravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemiaAcute compartment syndrome: an unusual presentation of gemfibrozil induced myositisTolerability of fibric acids. comparative data and biochemical basesGemfibrozil-lovastatin therapy for primary hyperlipoproteinemiasMusculoskeletal Complications After Renal Transplantation: Pathogenesis and TreatmentLovastatin-Induced Rhabdomyolysis in the Absence of Concomitant DrugsHyperlipidemiasRhabdomyolyse causée par la simvastatine chez un transplanté cardiaque sous ciclosporineDrug-induced myopathiesPravastatin Sodium, a New Hmg-CoA Reductase InhibitorDrugs in the Management of Lipid DisordersLovastatin therapy for cholesterol ester storage disease in two sistersDrugs affecting lipid metabolism 1 February 1990Volume 112, Issue 3Page: 228-230KeywordsDrug metabolismDrugsEnzymesHospital medicineImmunoassaysImmunosuppressivesMyalgiaPatientsResearch laboratoriesRhabdomyolysis Issue Published: 1 February 1990 PDF DownloadLoading ...